Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy,Cancer Biotherapy and Radiopharmaceuticals

当前位置： X-MOL 学术 › Cancer Biother. Radiopharm. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Therapeutic Multidose Preparation of a Ready-to-Use 177Lu-PSMA-617 Using Carrier Added Lutetium-177 in a Hospital Radiopharmacy and Its Clinical Efficacy
Cancer Biotherapy and Radiopharmaceuticals ( IF 2.4 ) Pub Date : 2021-10-13 , DOI: 10.1089/cbr.2020.4261
Avik Chakraborty _{1,

2} , Arpit Mitra ₃ , Megha Tawate ₁ , Sudip Sahoo ₁ , Sangita Lad ₁ , Sutapa Rakshit ₁ , Sujay Gaikwad _{1,

2} , Sandip Basu _{1,

2} , Hemant Shimpi ₁ , Sharmila Banerjee _{1,

2,

3}

Affiliation

Introduction: [¹⁷⁷Lu]Lu-prostate-specific membrane antigen (PSMA)-617 has emerged as a promising radiopharmaceutical for targeting PSMA in metastatic castrate-resistant prostate carcinoma (mCRPC). We have optimized the radiolabeling protocol for a multidose formulation (27–28.8 GBq equivalent to 6–7 patient-doses) of [¹⁷⁷Lu]Lu-PSMA-617 using [¹⁷⁷Lu]Lu³⁺ produced via ¹⁷⁶Lu(n,γ)¹⁷⁷Lu route with moderate specific activity (0.66–0.81 GBq/μg).

中文翻译：

在医院放射性药物中使用载体添加镥-177的即用型177Lu-PSMA-617的治疗性多剂量制剂及其临床疗效

简介： [¹⁷⁷ Lu]Lu-前列腺特异性膜抗原 (PSMA)-617 已成为一种很有前途的放射性药物，可用于靶向 PSMA 治疗转移性去势抵抗性前列腺癌 (mCRPC)。我们使用通过¹⁷⁶^Lu⁽ⁿ ,γ)¹⁷⁷ Lu 路线，具有中等比活性 (0.66–0.81 GBq/μg)。

更新日期：2021-10-18

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11